staurosporine has been researched along with cladribine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Albertioni, F; Chandra, J; Gogvadze, V; Kaufmann, SH; Mansson, E; Orrenius, S | 1 |
| Aichberger, KJ; Böhm, A; Derdak, S; Fabbro, D; Gleixner, KV; Gruze, A; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
| Pardanani, A | 3 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Metzgeroth, G; Reiter, A; Schwaab, J | 1 |
3 review(s) available for staurosporine and cladribine
| Article | Year |
|---|---|
Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Examination; Cell Lineage; Cladribine; Clinical Trials as Topic; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Immunophenotyping; Interferon-alpha; Leukemia, Mast-Cell; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Organ Specificity; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Tryptases | 2012 |
[Systemic mastocytosis].
Topics: Biopsy, Needle; Bone Marrow; Cladribine; DNA Mutational Analysis; Humans; Interferon-alpha; Mastocytosis, Systemic; Prognosis; Proto-Oncogene Proteins c-kit; Staurosporine | 2014 |
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Management; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Survival Analysis; Transplantation, Homologous; Tryptases | 2019 |
1 trial(s) available for staurosporine and cladribine
| Article | Year |
|---|---|
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
4 other study(ies) available for staurosporine and cladribine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Apoptosis; Calcium Signaling; Caspases; Chelating Agents; Chromatography, High Pressure Liquid; Cladribine; Cytochrome c Group; Deoxyadenine Nucleotides; Deoxycytidine Kinase; DNA Fragmentation; Drug Resistance, Neoplasm; Egtazic Acid; Enzyme Activation; Intracellular Membranes; Membrane Potentials; Mitochondria; Neoplasm Proteins; Neoplastic Stem Cells; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-bcl-2; Staurosporine; Thapsigargin | 2002 |
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Topics: Anti-Bacterial Agents; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; CD2 Antigens; Cell Proliferation; Cells, Cultured; Cladribine; Down-Regulation; Doxycycline; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; Female; Humans; Imatinib Mesylate; Immunophenotyping; In Vitro Techniques; Leukemia, Mast-Cell; Middle Aged; Mutation; Phosphorylation; Piperazines; Platelet Membrane Glycoproteins; Protein Kinase C; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tetraspanin 30 | 2006 |
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles | 2011 |